Biogen heads into Q1 earnings with new drugs like Skyclarys and Zurzuvae driving growth as legacy MS products face rising competitive pressure.

The manufacturing of the drug will be retained by TJ Biopharma at its site in Hangzhou, which would make felzartamab China’s ...

April 20 (Reuters) - Biogen said on Monday it had agreed to pay up to $850 million to acquire exclusive rights in Greater ...

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights ...

Fintel reports that on April 22, 2026, UBS upgraded their outlook for Biogen (NasdaqGS:BIIB) from Neutral to Buy. Analyst ...

Biogen (NASDAQ:BIIB | BIIB Price Prediction) stock just earned a strong endorsement from Wells Fargo on Monday, as analyst ...

'Mad Money' host Jim Cramer weighs in on stocks including: AES, InterDigital, Infleqtion, Netskope, and Biogen.

Shares of Biogen Inc. BIIB slipped 1.15% to $187.88 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.41% to 7,108.40 and ...

Biogen (BIIB) stock is in focus as the company inks a deal worth up to $850M with TJ Bio to buy Greater China rights to ...

Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building ...

Biogen has agreed to pay up to $850 million to acquire TJ Bio's exclusive rights to felzartamab in the Greater China region, giving it worldwide rights to the investigational drug that is currently in ...

In a report released today, Emily Field from Barclays maintained a Hold rating on Biogen, with a price target of $185.00. According to TipRanks, Field is a 3-star analyst with an average return of 1.4 ...